<DOC>
	<DOCNO>NCT01066013</DOCNO>
	<brief_summary>The purpose pilot study assess impact antibiotic de-escalation strategy clinical outcome ( clinical cure improvement ) medical patient related usage broad-spectrum antimicrobial agent .</brief_summary>
	<brief_title>Antimicrobial De-escalation Strategy Medical Patients</brief_title>
	<detailed_description>This open-label , case-control , pilot study involve medical patient serious infection prescribe meropenem piperacillin/tazobactam , Surrey Memorial Hospital . Patients experimental arm ( case ) require provide inform consent . A team consist infectious disease specialist , medical microbiologist clinical pharmacist prospectively assess antimicrobial therapy enrol subject prospective arm make recommendation antimicrobial de-escalation . The control group consist subject draw historic data patient medical unit ( ) match base age , sex , use broadspectrum antibiotic ( meropenem piperacillin/tazobactam ) infectious disease diagnosis .</detailed_description>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Age 19 year Suspected confirmed infection Meropenem and/or Piperacillin/Tazobactam prescribed . This include patient concomitant antibiotic ( ) Vancomycin Subject admit SMH medical unit ( ) Pregnant patient ( patient wish become pregnant ) Age le 19 year Granulocytopenia ( &lt; 1x109/L ) Allergy intolerance meropenem piperacillintazobactam . Febrile Neutropenia Cystic Fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Antimicrobial De escalation</keyword>
	<keyword>Meropenem</keyword>
	<keyword>Piperacillin tazobactam</keyword>
	<keyword>Medical patient</keyword>
	<keyword>Appropriate use</keyword>
	<keyword>Cost saving</keyword>
	<keyword>Antimicrobial De-escalation strategy</keyword>
</DOC>